ArticleScientific reports2025
Evaluation of the potential for diagnosis of fungal keratitis using a Fusarium-specific antibody.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The increasing number of contact lens users correlates with a rise in the incidence of fungal keratitis. Fungal keratitis can lead to blindness if not treated promptly, and its early symptoms are similar to those of bacterial and amoebic keratitis, making rapid diagnosis challenging. This study aimed to assess the potential of using a peptide antibody against the fungal-specific protein ERG24, which encodes sterol C-14 reductase, to differentiate fungal keratitis from other forms of keratitis. The specificity of the ERG24 antibody was assessed through Western blot and enzyme-linked immunosorbent assay (ELISA). Immunocytochemistry (ICC) was performed by co-culturing two types of fungi, Acanthamoeba, and two bacterial strains with human corneal epithelial (HCE) cells. Additionally, to evaluate the diagnostic potential of the ERG24 antibody, animal models of fungal, amoebic, and bacterial keratitis were developed, and ELISA was conducted on tear and ocular lysates from these models. The results demonstrated that the antibody specifically reacted with Fusarium solani in Western blot, and both ELISA and ICC confirmed that the ERG24 antibody did not react with HCE cells, Acanthamoeba, or bacteria, but was specific to the two fungal species. In vivo experiments further showed that the ERG24 antibody significantly detected F. solani in tear-wash samples and eyeball lysates from the fungal keratitis model, without reacting with samples from amoebic and bacterial keratitis models. This study suggests that the ERG24 peptide antibody could provide valuable information for developing differential diagnostic methods for fungal keratitis compared to other forms of keratitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.